Study of CFTR-modulator effects using body samples
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You and your CF specialist have decided to start CFTR-modulator therapy
- You (and your caregiver, if needed) can sign the informed consent form
- If the study requires it, your assent form is signed (if you’re a minor)
- You are not currently taking part in another research drug study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study looks for simple signals (markers) that may show whether cystic fibrosis treatments are working. It includes people who take CF “modulator” medicines like ivacaftor, people who don’t, and people whose cystic fibrosis was ruled out after testing.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This observational study follows people with cystic fibrosis (CF) to understand the long-term impact of CFTR modulator medicines. It may help researchers see how these treatments work over time in real life.
This study is looking at how a new combination medicine (Trikafta) affects the lungs and gut in people with cystic fibrosis who carry the DeltaF508 mutation. It aims to understand how the medicine works in the body.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.